Abide Therapeutics has entered into a strategic collaboration with Celgene Corp. to discover and develop new drugs in inflammation and immunology using Abides technology platform to selectively target serine hydrolases, one of the largest enzyme families involved in regulating physiology. Included in the collaboration is Abide’s lead compound, AB101131, which is projected to enter first human studies in 2015. Abide expects to generate another three to four developmental candidates during t...